28 January 2020
Visiongain has launched a new pharma report The Global Respiratory Inhalers Market : Dry Powder Inhalers, Single-dose DPI, Multi-dose DPI, Metered Dose Inhalers, Nebulizers, Jet Nebulizers, Ultrasonic Nebulizers, Vibrating-mesh Nebulizers, Asthma, COPD, Others.
Respiratory inhalers are used to relieve the symptoms of asthma and COPD and prevent exacerbations, which can lead to expensive hospital stays for patients and increase the risk of mortality. The market is maturing with the launch of generic products expected during the forecast period. The launch of advanced products such as triple combination therapy and focus on development of e-devices are expected to drive the market growth.
Chekeh Mboge, the lead analyst of the report commented "Emerging countries will experience accelerated growth in the respiratory inhaler market, due to higher standards of living, rising life expectancy and an increase in urbanization. This demand alone will not mitigate falling revenues, and with generics becoming increasingly available due to past and upcoming patent expiry’s, traditional pharma companies are focusing on developing newer inhaler technology. These devices, which track patient usage and share with relevant HCPs, will tackle the huge unmet needs of patients: namely, lack of adherence and improper inhaler techniques. Digital inhalers will lead the way towards a patient pathway characterized by personalization and precision medicine. In addition to providing better health outcomes, these new digital inhalers will act as a high barrier to entry ceiling, to counter generic competition and will significantly drive growth in the market."
Leading companies featured in the report include AstraZeneca, Boehringer Ingelheim, Chiesi, Farmaceutici S.p.A., GlaxoSmithKline (GSK), Merck & Co., Novartis, Teva and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Due to increases in the therapies in progress, the dosages provided, & the patient populations targeted, viral vector production capacity has become increasingly reduced in recent years. The condition is aggravated by COVID-19.
03 December 2020
Drugs Abuse has risen very significantly in few last year as compared to previous once and expected to continuously rise over the forecast period. The increase in the drugs abuse creates a huge demand for the drugs of abuse testing products.
03 December 2020
Continuous increasing prevalence of chronic pain is increasing demand for controlled substance as treatment for Chronic pain. Due to which increasing prevalence of chronic pain around the world is working as a driver for the controlled substance market.
03 December 2020
All regions are facing rapid growth in the companion animal population. Companion animal are at high risk of developing various diseases for which companion animal require timely diagnosis for the identification, detection and treatment for life causing diseases.